China Pharma regains NYSE American price compliance but remains under equity plan with delisting risk

CHINA PHARMA HOLDINGS, INC.

Resolved low selling price deficiency via 1-for-10 reverse stock split on March 6, 2023.
Still non-compliant with stockholders' equity standards (Sections 1003(a)(ii) and (iii)).
Must achieve full compliance by December 15, 2023 or face delisting proceedings.
".BC" indicator remains on ticker CPHI.
If average share price falls below $0.20 over 30 days, immediate review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.